Elliot Crane, MD
Cornea and External Diseases Specialist · South Orange, NJNPI 1710411566
Payments from drug & device makers
Across 198 payments — averaging $255.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$42K
- Glaukos Corporation$2K
- Tarsus Pharmaceuticals, Inc.$2K
- Bausch & Lomb Americas Inc.$1K
- Alcon$885
- Dompe US, Inc.$672
- plus $2K from 11 others
What the payments were for
- Consulting fees$1,50013%
- Travel & lodging$1,70215%
- Food & beverage$8,10772%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 45 | $41,843 |
| Glaukos Corporation | 17 | $1,993 |
| Tarsus Pharmaceuticals, Inc. | 11 | $1,773 |
| Bausch & Lomb Americas Inc. | 38 | $1,165 |
| Alcon | 20 | $885 |
| Dompe US, Inc. | 11 | $672 |
| Sight Sciences, Inc. | 9 | $590 |
| Sun Pharmaceutical Industries Inc. | 14 | $373 |
| Amgen | 3 | $359 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $191 |
| AbbVie | 7 | $149 |
| Rxsight Inc | 2 | $127 |
| Novartis | 7 | $114 |
| Mallinckrodt Hospital Products Inc. | 4 | $110 |
| Oyster Point Pharma, Inc. | 6 | $107 |
| Genentech USA, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$1,500
- Oxervate$482
- MIEBO$368
- XIIDRA$368
- TEPEZZA$359
- Tecnis IOL$310
- iDose$307
- Clareon$287
- Prokera$222
- AmnioGraft$222
- OMNI(R) SURGICAL SYSTEM (US)$203
- SION SURGICAL INSTRUMENT$203
- iStent infinite Trabecular Micro-Bypass System Model iS3$187
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$187
- TearCare SmartLid$180
- TEARCARE(TM) (2.2) SYSTEM KIT$180
- iStent Inject Trabecular Micro-Bypass System$171
- IACCESS$152
- iStent inject W$152
- ARGOS$141
How this compares
Too few cornea and external diseases specialist providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 605 | $479,749 |
| RestasisCyclosporine | 120 | $91,828 |
| XdemvyLotilaner | 33 | $62,197 |
| MieboPerfluorohexyloctane/Pf | 58 | $48,963 |
| CequaCyclosporine | 38 | $46,375 |
| LumiganBimatoprost | 90 | $43,158 |
| VyzultaLatanoprostene Bunod | 125 | $37,107 |
| TyrvayaVarenicline Tartrate | 41 | $26,579 |
| RhopressaNetarsudil Mesylate | 49 | $18,279 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $16,073 |
| CombiganBrimonidine Tartrate/Timolol | 50 | $14,756 |
| Brimonidine Tartrate | 133 | $11,328 |
| Cyclosporine | 27 | $10,836 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 49 | $10,296 |
| Prednisolone Acetate | 251 | $7,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,165 | $565,820788 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $149 | $156,534285 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,773 | $62,19733 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $373 | $46,37538 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $107 | $26,57941 claims |
| AlconSimbrinza | $885 | $10,29649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in South Orange
- Ekta PatelVineland$2K
- Aisha HasanParamus$966
- Sarah YuPalisades Park$737
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.